SI9520153B - Variante humane DNaze I - Google Patents

Variante humane DNaze I Download PDF

Info

Publication number
SI9520153B
SI9520153B SI9520153A SI9520153A SI9520153B SI 9520153 B SI9520153 B SI 9520153B SI 9520153 A SI9520153 A SI 9520153A SI 9520153 A SI9520153 A SI 9520153A SI 9520153 B SI9520153 B SI 9520153B
Authority
SI
Slovenia
Prior art keywords
human dnase
amino acid
actin
variant
acid sequence
Prior art date
Application number
SI9520153A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9520153A (sl
Inventor
Robert A. Lazarus
Steven Shak
Jana S. Ulmer
Original Assignee
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22248728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9520153(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech, Inc. filed Critical Genentech, Inc.
Publication of SI9520153A publication Critical patent/SI9520153A/sl
Publication of SI9520153B publication Critical patent/SI9520153B/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI9520153A 1995-02-24 1995-02-24 Variante humane DNaze I SI9520153B (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1995/002366 WO1996026278A1 (en) 1995-02-24 1995-02-24 HUMAN DNase I VARIANTS

Publications (2)

Publication Number Publication Date
SI9520153A SI9520153A (sl) 1998-06-30
SI9520153B true SI9520153B (sl) 2004-10-31

Family

ID=22248728

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9520153A SI9520153B (sl) 1995-02-24 1995-02-24 Variante humane DNaze I

Country Status (22)

Country Link
EP (1) EP0811068B1 (cs)
JP (1) JPH11505408A (cs)
AT (1) ATE230027T1 (cs)
AU (1) AU720635B2 (cs)
BG (1) BG64061B1 (cs)
BR (1) BR9510323A (cs)
CA (1) CA2210871C (cs)
CZ (1) CZ288633B6 (cs)
DE (1) DE69529235T2 (cs)
DK (1) DK0811068T3 (cs)
ES (1) ES2188653T3 (cs)
HU (1) HU223272B1 (cs)
MX (1) MX9706428A (cs)
NO (1) NO326612B1 (cs)
PL (1) PL180773B1 (cs)
PT (1) PT811068E (cs)
RU (1) RU2215787C2 (cs)
SI (1) SI9520153B (cs)
SK (1) SK283850B6 (cs)
UA (2) UA66749C2 (cs)
WO (1) WO1996026278A1 (cs)
ZA (1) ZA961419B (cs)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
EP1433842B1 (en) 2002-12-18 2011-01-05 Roche Diagnostics GmbH Recombinant bovine pancreatic desoxyribonuclease I with high specific activity
DE60335602D1 (de) 2002-12-18 2011-02-17 Roche Diagnostics Gmbh Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE176924T1 (de) * 1988-12-23 1999-03-15 Genentech Inc Verfahren zur herstellung von menschlicher dnase
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I

Also Published As

Publication number Publication date
WO1996026278A1 (en) 1996-08-29
BG64061B1 (bg) 2003-11-28
NO973876L (no) 1997-10-24
ES2188653T3 (es) 2003-07-01
SI9520153A (sl) 1998-06-30
HUT77422A (hu) 1998-04-28
EP0811068B1 (en) 2002-12-18
MX9706428A (es) 1997-11-29
PL180773B1 (pl) 2001-04-30
RU2215787C2 (ru) 2003-11-10
CA2210871A1 (en) 1996-08-29
BG101846A (en) 1998-07-31
UA66749C2 (en) 2004-06-15
SK114797A3 (en) 1998-02-04
SK283850B6 (sk) 2004-03-02
CZ267797A3 (cs) 1998-01-14
AU720635B2 (en) 2000-06-08
CA2210871C (en) 2009-04-07
DE69529235D1 (de) 2003-01-30
BR9510323A (pt) 1997-11-11
NO973876D0 (no) 1997-08-22
ZA961419B (en) 1997-08-22
DK0811068T3 (da) 2003-03-10
CZ288633B6 (cs) 2001-08-15
ATE230027T1 (de) 2003-01-15
DE69529235T2 (de) 2003-09-04
HU223272B1 (hu) 2004-04-28
JPH11505408A (ja) 1999-05-21
AU1970395A (en) 1996-09-11
EP0811068A1 (en) 1997-12-10
UA65523C2 (en) 2004-04-15
NO326612B1 (no) 2009-01-19
PL321890A1 (en) 1997-12-22
PT811068E (pt) 2003-04-30

Similar Documents

Publication Publication Date Title
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
ES2124203T1 (es) Inhibidores de elastasa de neutrofilos humanos y catepsina g humana.
GEP20022788B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
PT910647E (pt) Variantes hiperactivas da dnase i humana
ATE67505T1 (de) Tetrapyrrolverbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
HUP9901144A2 (hu) Hatóanyagként klopidogrel és egy antitrombotikum új kombinációját tartalmazó gyógyszerkészítmények
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
HUP9602498A2 (hu) Antimikrobiális hatású gyógyászati készítmények
SI9520153B (sl) Variante humane DNaze I
HRP20030215B1 (en) Chemokine mutants in the tratment of multiple sclerosis
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
CA2211413A1 (en) Human dnase i variants
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
BG101847A (en) Human dnase i variants
CA2242562A1 (en) Human dnase resistant to actin inhibition

Legal Events

Date Code Title Description
IF Valid on the event date